2023
David, C. A. W., de la Fonteyne-Blankestijn, L. J. J., Vermeulen, J. P., Plant-Hately, A. J., Vandebriel, R. J., & Liptrott, N. J. (2023). Application of KU812 cells for assessing complement activation related effects by nano(bio)materials.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 163, 114841. doi:10.1016/j.biopha.2023.114841DOI: 10.1016/j.biopha.2023.114841
Amadeo, F., Hanson, V., Liptrott, N. J., Wilm, B., Murray, P., & Taylor, A. (2023). Fate of intravenously administered umbilical cord mesenchymal stromal cells and interactions with the host's immune system. BIOMEDICINE & PHARMACOTHERAPY, 159. doi:10.1016/j.biopha.2022.114191DOI: 10.1016/j.biopha.2022.114191
2022
Plant-Hately, A. J., Eryilmaz, B., David, C. A. W., Brain, D. E., Heaton, B. J., Perrie, Y., & Liptrott, N. J. (2022). Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics. PHARMACEUTICS, 14(11). doi:10.3390/pharmaceutics14112470DOI: 10.3390/pharmaceutics14112470
Intravenous administration of human umbilical cord mesenchymal stromal cells leads to an inflammatory response in the lung (Preprint)
DOI: 10.1101/2022.09.26.509547
Vandebriel, R. J., David, C. A. W., Vermeulen, J. P., & Liptrott, N. J. (2022). An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 12(9), 2225-2242. doi:10.1007/s13346-022-01206-6DOI: 10.1007/s13346-022-01206-6
Minnema, J., Borgos, S. E. F., Liptrott, N., Vandebriel, R., & Delmaar, C. (2022). Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances. DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 12(9), 2132-2144. doi:10.1007/s13346-022-01159-wDOI: 10.1007/s13346-022-01159-w
Shakil, A., Hern, F. Y., Liu, C., Temburnikar, K., Chambon, P., Liptrott, N., . . . Rannard, S. P. (2022). Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. JOURNAL OF MATERIALS CHEMISTRY B, 10(23), 4395-4404. doi:10.1039/d2tb00825dDOI: 10.1039/d2tb00825d
Heaton, B. J., Jensen, R. L., Line, J., David, C. A. W., Brain, D. E., Chadwick, A. E., & Liptrott, N. J. (2022). Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1. BIOMEDICINE & PHARMACOTHERAPY, 150. doi:10.1016/j.biopha.2022.112999DOI: 10.1016/j.biopha.2022.112999
Effects of nano-enabled chemotherapeutic delivery systems upon tissue based immune cells. (Poster)
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2022). Effects of nano-enabled chemotherapeutic delivery systems upon tissue based immune cells.. Poster session presented at the meeting of British Toxicology Society 2022. Newcastle, UK.
Amadeo, F., Plagge, A., Chacko, A., Wilm, B., Hanson, V., Liptrott, N., . . . Taylor, A. (2022). Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 49(3), 796-808. doi:10.1007/s00259-021-05439-4DOI: 10.1007/s00259-021-05439-4
PBPK Modelling for Intratumoral Biodistribution of Magnetic Iron Oxide Nanoparticles (Conference Paper)
Mohamed, D. A., Howarth, A., Abasolo, I., Montanha, M., Llaguno, M., Southern, P., . . . Liptrott, N. (2022, April 2). PBPK Modelling for Intratumoral Biodistribution of Magnetic Iron Oxide Nanoparticles. In Proceedings of the 7th World Congress on Recent Advances in Nanotechnology. Avestia Publishing. doi:10.11159/nddte22.140DOI: 10.11159/nddte22.140
2021
Assessment of cell-mediated effects, related to infusion reactions to nano-enabled chemotherapeutic delivery systems. (Poster)
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2021). Assessment of cell-mediated effects, related to infusion reactions to nano-enabled chemotherapeutic delivery systems.. Poster session presented at the meeting of Liverpool Cancer Research Institute, Scientific Symposium. Liverpool.
Brain, D., Plant-Hately, A., Heaton, B., Arshad, U., David, C., Hedrich, C., . . . Liptrott, N. J. (2021). Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. ADVANCED DRUG DELIVERY REVIEWS, 178. doi:10.1016/j.addr.2021.113848DOI: 10.1016/j.addr.2021.113848
Halamoda-Kenzaoui, B., Vandebriel, R. J., Howarth, A., Siccardi, M., David, C. A. W., Liptrott, N. J., . . . Caputo, F. (2021). Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. JOURNAL OF CONTROLLED RELEASE, 336, 192-206. doi:10.1016/j.jconrel.2021.06.016DOI: 10.1016/j.jconrel.2021.06.016
David, C. A. W., del Castillo Busto, M. E., Cuello-Nunez, S., Goenaga-Infante, H., Barrow, M., Fernig, D. G., . . . Liptrott, N. J. (2021). Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles. CELL AND BIOSCIENCE, 11(1). doi:10.1186/s13578-021-00648-8DOI: 10.1186/s13578-021-00648-8
Heal, J. R., Sheridan, J. M., Kulkarni, M., Liptrott, N., Egan, D., Khoo, S., . . . Hamilton, W. D. O. (2021). AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 61(4), 1778-1788. doi:10.1021/acs.jcim.0c01261DOI: 10.1021/acs.jcim.0c01261
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1DOI: 10.26434/chemrxiv.13587035.v1
Avila, Y. I., Chandler, M., Cedrone, E., Newton, H. S., Richardson, M., Xu, J., . . . Dobrovolskaia, M. A. (2021). Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier. MOLECULES, 26(3). doi:10.3390/molecules26030652DOI: 10.3390/molecules26030652
2020
Involvement of pattern recognition receptors in the immune response to lipid-based nanoparticles - a comparison of basophil and mast cell lines. (Poster)
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2020). Involvement of pattern recognition receptors in the immune response to lipid-based nanoparticles - a comparison of basophil and mast cell lines.. Poster session presented at the meeting of British Pharmacological Society. Online.
David, C. A. W., Barrow, M., Murray, P., Rosseinsky, M. J., Owen, A., & Liptrott, N. J. (n.d.). In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells. International Journal of Molecular Sciences, 21(16), 5610. doi:10.3390/ijms21165610DOI: 10.3390/ijms21165610
Hobson, J. J., Rannard, S. P., Owen, A., & Liptrott, N. J. (2020). Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity. Nanomedicine. doi:10.2217/nnm-2019-0447DOI: 10.2217/nnm-2019-0447
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130DOI: 10.1101/2020.05.01.20087130
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379DOI: 10.1101/2020.04.16.20068379
Arshad, U., Sutton, P. A., Ashford, M. B., Treacher, K. E., Liptrott, N. J., Rannard, S. P., . . . Owen, A. (2020). Critical considerations for targeting colorectal liver metastases with nanotechnology. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 12(2). doi:10.1002/wnan.1588DOI: 10.1002/wnan.1588
2019
Recognition of liposomal nanoparticles by basophils – linking their activation to the induction of complement activation related pseudoallergy. All have the same author lists, by Plant-Hately, Alexander (Poster)
Plant-Hately, A., Eryilaz, B., Perrie, Y., & Liptrott, N. (2019). Recognition of liposomal nanoparticles by basophils – linking their activation to the induction of complement activation related pseudoallergy. All have the same author lists, by Plant-Hately, Alexander. Poster session presented at the meeting of British Society of Immunology.
Hannon, G., Lysaght, J., Liptrott, N. J., & Prina-Mello, A. (2019). Immunotoxicity Considerations for Next Generation Cancer Nanomedicines. ADVANCED SCIENCE, 6(19). doi:10.1002/advs.201900133DOI: 10.1002/advs.201900133
Halamoda-Kenzaoui, B., Baconnier, S., Bastogne, T., Bazile, D., Boisseau, P., Borchard, G., . . . Bremer-Hoffmann, S. (2019). Bridging communities in the field of nanomedicine. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 106, 187-196. doi:10.1016/j.yrtph.2019.04.011DOI: 10.1016/j.yrtph.2019.04.011
Tatham, L. M., Liptrott, N. J., Rannard, S. P., & Owen, A. (2019). Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?. MOLECULES, 24(15). doi:10.3390/molecules24152685DOI: 10.3390/molecules24152685
Initial assessment of the suitability of Galleria mellonella for the study of long acting formulations. (Conference Paper)
Neary, M., Sharp, J., Curley, P., Whiteford, S., Liptrott, N., & Owen, A. (2019). Initial assessment of the suitability of Galleria mellonella for the study of long acting formulations.. In Early Career Researcher Meeting British Society of Nanomedicine. Glasgow.
Urban, P., Liptrott, N. J., & Bremer, S. (2019). Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 11(3). doi:10.1002/wnan.1546DOI: 10.1002/wnan.1546
2018
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004DOI: 10.1016/j.dmpk.2018.01.004
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2018). Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems. JOURNAL OF NANOBIOTECHNOLOGY, 16. doi:10.1186/s12951-018-0349-yDOI: 10.1186/s12951-018-0349-y
Curley, P., Liptrott, N. J., & Owen, A. (2018). Advances in nanomedicine drug delivery applications for HIV therapy. FUTURE SCIENCE OA, 4(1). doi:10.4155/fsoa-2017-0069DOI: 10.4155/fsoa-2017-0069
Investigation of KU-812 cells as an in vitro model for basophil activation and assessment of complement related interactions. (Poster)
David, C., Plant-Hately, A. J., & Liptrott, N. J. (2018). Investigation of KU-812 cells as an in vitro model for basophil activation and assessment of complement related interactions.. Poster session presented at the meeting of CLINAM. Basel.
Potential for immune modulation by inhibition of autophagic processes. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2018). Potential for immune modulation by inhibition of autophagic processes.. Poster session presented at the meeting of Nanomedicine's Early Career Researchers Meeting. London.
2017
Chan, C., Martin, P., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2017). Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. PHARMACOLOGY RESEARCH & PERSPECTIVES, 5(5). doi:10.1002/prp2.359DOI: 10.1002/prp2.359
Curley, P., Giardiello, M., Liptrott, N. J., Dickens, D., Moss, D. M., Hobson, J. J., . . . Owen, A. (2017). In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2(3), 157-169. doi:10.1002/jin2.32DOI: 10.1002/jin2.32
Liptrott, N. J., Giardiello, M., McDonald, T. O., Rannard, S. P., & Owen, A. (2017). Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. NANOMEDICINE, 12(17), 2043-2054. doi:10.2217/nnm-2017-0095DOI: 10.2217/nnm-2017-0095
Sharkey, J., Starkey Lewis, P. J., Barrow, M., Alwahsh, S. M., Noble, J., Livingstone, E., . . . Park, B. K. (2017). Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance-based detection in vivo.. Cytotherapy, 19(4), 555-569. doi:10.1016/j.jcyt.2017.01.003DOI: 10.1016/j.jcyt.2017.01.003
David, C., Ahmed, F., Owen, A., & Liptrott, N. (2017). Modulation of inflammasome activation through manipulation of autophagic processes in primary human immune cells.. Journal of Interdisciplinary Nanomedicine.
Rosslein, M., Liptrott, N. J., Owen, A., Boisseau, P., Wick, P., & Herrmann, I. K. (2017). Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines. NANOTOXICOLOGY, 11(2), 147-149. doi:10.1080/17435390.2017.1279361DOI: 10.1080/17435390.2017.1279361
Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems. (Poster)
David, C., Giardiello, M., Rannard, S. P., Owen, A., & Liptrott, N. J. (2017). Assessment of the potential interactions of hyperbranched polydendrons with immunological and haematological systems.. Poster session presented at the meeting of BSNM Early Career Researchers' Meeting. Belfast.
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16DOI: 10.1128/AAC.01841-16
2016
Giardiello, M., Liptrott, M. J., McDonald, T. O., Moss, D., Siccardi, M., Martin, P., . . . Owen, A. (2016). Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7. doi:10.1038/ncomms13184DOI: 10.1038/ncomms13184
Siccardi, M., Martin, P., Smith, D., Curley, P., McDonald, T., Giardiello, M., . . . Owen, A. (2016). Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.. Journal of interdisciplinary nanomedicine, 1(3), 110-123. doi:10.1002/jin2.21DOI: 10.1002/jin2.21
Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma (Journal article)
McFaul, K., Liptrott, N., Cox, A., Martin, P., Egan, D., Owen, A., . . . Boffito, M. (2016). Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV-infected individuals with lymphoma. HIV CLINICAL TRIALS, 17(5), 197-203. doi:10.1080/15284336.2016.1210719DOI: 10.1080/15284336.2016.1210719
David, C. A. W., Owen, A., & Liptrott, N. J. (2016). Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches. NANOMEDICINE, 11(11), 1447-1464. doi:10.2217/nnm-2016-0017DOI: 10.2217/nnm-2016-0017
Handbook of Immunological Properties of Engineered Nanomaterials (Chapter)
Dobrovolskaia, M. A., & McNeil, S. E. (n.d.). Handbook of Immunological Properties of Engineered Nanomaterials. WORLD SCIENTIFIC. doi:10.1142/9677DOI: 10.1142/9677
Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles (Journal article)
Silva, A. H., Locatelli, C., Filippin-Monteiro, F. B., Martin, P., Liptrott, N. J., Zanetti-Ramos, B. G., . . . Creczynski-Pasa, T. B. (2016). Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles. TOXICOLOGY LETTERS, 246, 17-27. doi:10.1016/j.toxlet.2016.01.018DOI: 10.1016/j.toxlet.2016.01.018
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2016). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of University of Liverpool ITM Research Day. Liverpool.
2015
The Application of Nanotechnology to Drug Delivery in Medicine (Chapter)
McDonald, T. O., Siccardi, M., Moss, D., Liptrott, N., Giardiello, M., Rannard, S., & Owen, A. (2015). The Application of Nanotechnology to Drug Delivery in Medicine. In Nanoengineering (pp. 173-223). Elsevier. doi:10.1016/b978-0-444-62747-6.00007-5DOI: 10.1016/b978-0-444-62747-6.00007-5
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions (Journal article)
Liptrott, N. J., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2015). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. NANOMEDICINE, 10(9), 1407-1421. doi:10.2217/NNM.14.77DOI: 10.2217/NNM.14.77
Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2015). Determining the physicochemical characteristics of nanoparticles that relate to negative effects on cellular health using in vitro systems.. Poster session presented at the meeting of European Nanomedicine Meeting. Grenoble.
Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter (Journal article)
Moss, D. M., Liptrott, N. J., Siccardi, M., & Owen, A. (2015). Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. FRONTIERS IN PHARMACOLOGY, 6. doi:10.3389/fphar.2015.00078DOI: 10.3389/fphar.2015.00078
Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy. (Poster)
David, C., Liptrott, N. J., & Owen, A. (2015). Optimisation of higher throughput assays for assessing the impact of nanomaterials on autophagy.. Poster session presented at the meeting of University of Liverpool Poster Day. Liverpool.
Optimisation of methodology to assess the impact of nanomaterials on autophagy. (Poster)
David, C., Owen, A., & Liptrott, N. J. (2015). Optimisation of methodology to assess the impact of nanomaterials on autophagy.. Poster session presented at the meeting of BSNM Young Researcher Meeting. Liverpool.
Utility of kinetic measurement of oxidative stress in nanotoxicological assay development. (Poster)
David, C., Raymant, M. L., Owen, A., & Liptrott, N. J. (2015). Utility of kinetic measurement of oxidative stress in nanotoxicological assay development.. Poster session presented at the meeting of Nanotechnology in Medicine. Manchester.
2014
Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix' (Journal article)
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle-interactions with human lymphocytes by surface functionalization with a 'mixed-matrix'. Nanomedicine, 9(16), 2467-2479. doi:10.2217/nnm.14.38DOI: 10.2217/nnm.14.38
Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation (Journal article)
McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280DOI: 10.1002/adhm.201300280
Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions (Journal article)
Liptrott, N., Giardiello, M., Hunter, J. W., Tatham, L., Tidbury, L. R., Siccardi, M., . . . Owen, A. (2014). Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. Nanomedicine (London).
Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine (Poster)
Curley, P., Liptrott, N., Tatham, L., Siccardi, M., & Owen, A. (2014). Highlights of research at the University of Liverpool and activity of the British Society for Nanomedicine. Poster session presented at the meeting of 7th CLINAM Conference and Exhibition. Basel, Switzerland.
Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix' (Journal article)
Liptrott, N. J., Kendall, E., Nieves, D. J., Farrell, J., Rannard, S., Fernig, D. G., & Owen, A. (2014). Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'. Nanomedicine (London).
The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents (Poster)
Curley, P., Giardiello, M., Liptrott, N., Martin, P., McDonald, T., Siccardi, M., . . . Owen, A. (2014). The in vivo effects of solid drug nanoparticle and conventional efavirenz on anxiogenesis in rodents. Poster session presented at the meeting of 21st Conference on Retroviruses and Opportunistic Infections. Boston, USA.
2013
Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation (Journal article)
Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225DOI: 10.1093/jac/dkt225
Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro (Journal article)
Moss, D. M., Liptrott, N. J., Curley, P., Siccardi, M., Back, D. J., & Owen, A. (2013). Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(11), 5612-5618. doi:10.1128/AAC.01421-13DOI: 10.1128/AAC.01421-13
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli (Journal article)
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. JOURNAL OF MATERIALS CHEMISTRY B, 1(35), 4455-4465. doi:10.1039/c3tb20543fDOI: 10.1039/c3tb20543f
Immunological Safety Assessment and Viral Efficacy of Novel Pickering Stabilised Nanoemulsions Containing Lopinavir and Efavirenz (Conference Paper)
Hobson, J. J., Liptrott, N., Martin, P., Ford, J., Slater, R., Rannard, S., & Owen, A. (2013, June 23). Immunological Safety Assessment and Viral Efficacy of Novel Pickering Stabilised Nanoemulsions Containing Lopinavir and Efavirenz. In Clinical Nanomedicine and Targeted Medicine. Basel, Switzerland.
ENHANCED PHARMACOLOGICAL PROPERTIES OF EFAVIRENZ FORMULATED AS SOLID DRUG NANOPARTICLES (Conference Paper)
Martin, P., Liptrott, N. J., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). ENHANCED PHARMACOLOGICAL PROPERTIES OF EFAVIRENZ FORMULATED AS SOLID DRUG NANOPARTICLES. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta.
Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles (Conference Paper)
Martin, P., Liptrott, N., McDonald, T., Giardiello, M., Roberts, P., Curley, P., . . . Owen, A. (2013). Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.
High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli (Journal article)
McDonald, T. O., Tatham, L. M., Southworth, F. Y., Giardiello, M., Martin, P., Liptrott, N. J., . . . Rannard, S. P. (2013). High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli. Journal of Materials Chemistry B, 1(35), 4455. doi:10.1039/c3tb20543fDOI: 10.1039/c3tb20543f
Nanomedicines for HIV Therapy (Journal article)
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV Therapy. Therapeutic Delivery, 4(2), 149-152.
Nanomedicines for HIV therapy. (Journal article)
Siccardi, M., Martin, P., McDonald, T. O., Liptrott, N. J., Giardiello, M., Rannard, S., & Owen, A. (2013). Nanomedicines for HIV therapy.. Therapeutic delivery, 4(2), 153-156. doi:10.4155/tde.12.156DOI: 10.4155/tde.12.156
Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system (Poster)
Curley, P., Martin, P., Liptrott, N., Back, D., Owen, A., & Siccardi, M. (2013). Utilising In Vitro-In Vivo extrapolation to investigate efavirenz penetration into the central nervous system. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
2012
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82eDOI: 10.1097/fpc.0b013e32834dd82e
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS (Journal article)
Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82eDOI: 10.1097/FPC.0b013e32834dd82e
UPTAKE OF ANTIRETROVIRAL BASED SOLID DRUG NANOPARTICLES IN PRIMARY MONOCYTE DERIVED MACROPHAGES AND THEIR IMPACT ON MACROPHAGE FUNCTION (Conference Paper)
Liptrott, N. J., Martin, P., Giardiello, M., McDonald, T., Rannard, S. P., & Owen, A. (2012). UPTAKE OF ANTIRETROVIRAL BASED SOLID DRUG NANOPARTICLES IN PRIMARY MONOCYTE DERIVED MACROPHAGES AND THEIR IMPACT ON MACROPHAGE FUNCTION. In British Pharmacological Society Winter Meeting. London.
2011
IFN-gamma 874A > T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients (Journal article)
Liptrott, N. J., Egan, D., Back, D. J., & Owen, A. (2011). IFN-gamma 874A > T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV plus Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 442-445. doi:10.1097/QAI.0b013e318236441cDOI: 10.1097/QAI.0b013e318236441c
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67DOI: 10.1097/qai.0b013e3182364c67
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67DOI: 10.1097/QAI.0b013e3182364c67
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215DOI: 10.1093/infdis/jir215
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology (Poster)
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? (Journal article)
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 7(3), 341-352. doi:10.1517/17425255.2011.553600DOI: 10.1517/17425255.2011.553600
Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10DOI: 10.1128/AAC.00623-10
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction (Journal article)
Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., & al, E. (2011). Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. The Journal of Infectious diseases.
Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients (Journal article)
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(1), 72-75. doi:10.1128/AAC.00789-10DOI: 10.1128/AAC.00789-10
The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? (Journal article)
Liptrott, N. J., & Owen, A. (2011). The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?. Expert Opinion on Drug Metabolism and Toxicology.
2010
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms (Journal article)
Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02dDOI: 10.1097/FPC.0b013e328335b02d
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms (Journal article)
Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02dDOI: 10.1097/fpc.0b013e328335b02d
ASSOCIATION OF ABCC10 POLYMORPHISMS WITH NEVIRAPINE PLASMA CONCENTRATIONS IN THE GERMAN COMPETENCE NETWORK FOR HIV/AIDS (Conference Paper)
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . German Competence Network for HIV/AIDS. (2010). ASSOCIATION OF ABCC10 POLYMORPHISMS WITH NEVIRAPINE PLASMA CONCENTRATIONS IN THE GERMAN COMPETENCE NETWORK FOR HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.
Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS (Conference Paper)
Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.
GENETIC VARIANTS OF ABCC10 ARE ASSOCIATED WITH KIDNEY TUBULAR DYSFUNCTION IN PATIENTS TREATED WITH TENOFOVIR-CONTAINING REGIMENS (Conference Paper)
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). GENETIC VARIANTS OF ABCC10 ARE ASSOCIATED WITH KIDNEY TUBULAR DYSFUNCTION IN PATIENTS TREATED WITH TENOFOVIR-CONTAINING REGIMENS. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.
Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens (Conference Paper)
Pushpakom, S., Liptrott, N. J., RodrÃguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.
RALTEGRAVIR IS A SUBSTRATE FOR THE INFLUX TRANSPORTERS OAT1 AND PEPT1 AND THE EFFLUX TRANSPORTER PGP, BUT IS NOT TRANSPORTED BY OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, OR PEPT2 (Conference Paper)
Moss, D., Kwan, W. -S., Liptrott, N. J., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). RALTEGRAVIR IS A SUBSTRATE FOR THE INFLUX TRANSPORTERS OAT1 AND PEPT1 AND THE EFFLUX TRANSPORTER PGP, BUT IS NOT TRANSPORTED BY OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, OR PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco.
Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2 (Conference Paper)
Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.
Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir (Journal article)
Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.
2009
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC (Journal article)
Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.xDOI: 10.1111/j.1476-5381.2008.00050.x
EVALUATING THE EFFECT OF GENDER ON DARUNAVIR AND RITONAVIR EXPOSURE IN HIV INFECTED SUBJECTS (A POST-HOC ANALYSIS OF THE GRACE PK SUB-STUDY) (Conference Paper)
Else, L., Liptrott, N. J., Moss, D., Dutton, J., Fraser, W., Kakude, T., . . . Back, D. (2009). EVALUATING THE EFFECT OF GENDER ON DARUNAVIR AND RITONAVIR EXPOSURE IN HIV INFECTED SUBJECTS (A POST-HOC ANALYSIS OF THE GRACE PK SUB-STUDY). In 11th International Workshop on Clinical Pharmacology of HIV Therapy. Sorrento.
Liptrott, N. J. (2009). Pharmacological and Immunological factors that influence Antiretroviral Drug Response. (PhD Thesis, The University of Liverpool).
2008
Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry (Journal article)
Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010DOI: 10.1016/j.jim.2008.09.010
INTERFERON GAMMA GENOTYPE (874T>A) IS ASSOCIATED WITH CCR5 EXPRESSION IN HIV+ PATIENTS (Conference Paper)
Liptrott, N. J., Chandler, R., Khoo, S. H., Back, D. J., & Owen, A. (2008). INTERFERON GAMMA GENOTYPE (874T>A) IS ASSOCIATED WITH CCR5 EXPRESSION IN HIV+ PATIENTS. In 15th Conference on Retroviruses and Opportunistic Infections. Boston.
2007
INFLUENCE OF PD-1 GENOTYPE ON VIROLOGICAL AND IMMUNOLOGICAL RESPONSE IN PATIENTS INITIATING HAART (Conference Paper)
Liptrott, N. J., Mahungu, T., Youle, M., Johnson, M., Smith, C., Khoo, S. H., . . . Owen, A. (2007). INFLUENCE OF PD-1 GENOTYPE ON VIROLOGICAL AND IMMUNOLOGICAL RESPONSE IN PATIENTS INITIATING HAART. In 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles.
2006
RELATIONSHIP OF G516T POLYMORPHISM TO LYMPHOCYTE EXPRESSION OF CYP2B6 (Conference Paper)
Owen, A., Cook, C., Liptrott, N. J., Khoo, S., & Back, D. (2006). RELATIONSHIP OF G516T POLYMORPHISM TO LYMPHOCYTE EXPRESSION OF CYP2B6. In 13th Conference on Retroviruses and Opportunistic Infections. Denver.
The impact of cytokines on the expression of HIV-relevant, membrane-bound proteins (Conference Paper)
Liptrott, N., Back, D. J., Khoo, S. H., Penny, M., & Owen, A. (2006). The impact of cytokines on the expression of HIV-relevant, membrane-bound proteins. In DRUG METABOLISM REVIEWS Vol. 38 (pp. 124-125). Retrieved from https://www.webofscience.com/
Undated
Mellor, C. (n.d.). Developing safer HIV drugs: elucidating the mechanistic pathway of Tenofovir-induced cytotoxicity via mitochondrial dysfunction. (PhD Thesis, University of Liverpool).
